Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE versus METHADOSE.
HYDROCODONE BITARTRATE vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Adults: 5-10 mg orally every 4-6 hours as needed for pain; maximum 60 mg/day.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 3.5-4 hours in healthy adults. In patients with hepatic impairment (Child-Pugh Class B), half-life may be prolonged to ~6 hours. In renal impairment (CrCl <30 mL/min), half-life may be extended by 30-50%.
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Renal excretion of metabolites (primarily hydromorphone and norhydrocodone) accounts for approximately 99% of elimination, with less than 1% excreted unchanged. Biliary/fecal elimination is negligible.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist